Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Gene Therapy

A Glimpse Into The Expert Outlook On Voyager Therapeutics Through 5 Analysts

Across the recent three months, 5 analysts have shared their insights on Voyager Therapeutics (NASDAQ:VYGR), expressing a variety of opinions spanning from bullish to bearish.

3 Small-Cap Stocks That Are Ready to Rocket Higher

3 Small-Cap Stocks That Are Ready to Rocket Higher

With lower interest rates and lower corporate taxes more likely, it's a good time to consider three small-cap stocks that present a buying opportunity

RNA editing is the next frontier in gene therapy – here’s what you need to know

RNA editing is the next frontier in gene therapy – here’s what you need to know

The United States Food and Drug Administration has just approved the first-ever clinical trial that uses CRISPR-Cas13 RNA editing. Its aim is to treat an eye disease called wet age-related macular degeneration that causes vision loss in millions of older people worldwide.

The Conversation

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

3 Biotech Stocks Predicted to Surge on Medical Innovation

Biotech stocks are surging as groundbreaking neuroscience and gene therapy innovations take center stage. Amid this backdrop, investors might consider adding fundamentally strong biotech stocks like Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Gilead Sciences (GILD) to their portfolio for an impactful investment. Continue reading….

3 Pharma Stocks to Watch as Gene Therapy Gains Momentum

The pharma market shows promise as gene therapy gains momentum through rapid advancements that address complex diseases and improve treatment options. Given this favorable trend, it could be wise to watch strong pharma stocks such as Vertex Pharmaceuticals (VRTX), Wave Life Sciences (WVE), and Poseida Therapeutics (PSTX). Read more.

2 'Strong Buy'-Rated Stocks That Could Rally 39% to 48% in 2025

Both of these growth stocks are positioned for long-term success.

NHS to offer ‘life-changing’ gene therapy for blood disorder thalassaemia

Treatment may be offered to hundreds with severe form of disease, most often found in people of Mediterranean, Asian and Middle Eastern heritage

The Guardian - UK

inkl

Read news from The Economist, FT, and more,
with one subscription

Goldman Sachs Expects Market Sentiment To Support Smaller Firms, Sees Upside of up to 165% for Two Biotech Stocks

Goldman Sachs Expects Market Sentiment To Support Smaller Firms, Sees Upside of up to 165% for Two Biotech Stocks

Goldman Sachs analysts believe small- and equal-weight benchmarks will keep outperforming unless Q2 reports of big tech companies lead analysts to bump their sales forecasts for the latter half of this year and 2025.

International Business Times UK

Why Lexeo Therapeutics Collapsed 26%, Sacrificing A Breakout In Bearish Fashion

Why Lexeo Therapeutics Collapsed 26%, Sacrificing A Breakout In Bearish Fashion

Lexeo Therapeutics stock crashed Monday despite promising results for a gene therapy designed to treat heart problems of a genetic condition.

Investors Business Daily

Takeaways from AP's report on access to gene therapies for rare diseases

Takeaways from AP's report on access to gene therapies for rare diseases

The promise of gene therapy looms large for families dealing with rare, genetic disorders

The Independent UK

Gene therapy may cure rare diseases. But drugmakers have few incentives, leaving families desperate

Gene therapy may cure rare diseases. But drugmakers have few incentives, leaving families desperate

The promise of gene therapy looms large for families dealing with rare, genetic disorders

The Independent UK

Sarepta Catapults 30% After Hitting A 'Grand Slam' Approval In Muscular Dystrophy

Sarepta Catapults 30% After Hitting A 'Grand Slam' Approval In Muscular Dystrophy

Sarepta stock rocketed Friday after hitting a "grand slam" approval that expands the market for its Duchenne muscular dystrophy gene therapy more than tenfold, according to one estimate.

Investors Business Daily

Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test

Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test

Sarepta stock jumped Thursday after Pfizer's rival gene therapy for Duchenne muscular dystrophy failed in final-phase testing.

Investors Business Daily

When there’s no commercial incentive to develop gene therapy – hospitals will try to fill the gap

When there’s no commercial incentive to develop gene therapy – hospitals will try to fill the gap

Individually, rare diseases are rare, but there are so many rare diseases that over 400 million people are affected worldwide. Together, rare diseases aren’t so rare.

The Conversation

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Children born deaf can hear in both ears in world-first gene therapy trial

Given as an infusion into the ear, the treatment works by replacing the faulty DNA which causes a type of inherited deafness known as DFNB9.

The Guardian - UK

Gene therapy trial gives deaf children hearing in both ears

Study participants born unable to hear could locate sound sources, recognise speech and dance to music after treatment

The Independent UK

Two deaf children can hear in both ears after world-first treatment

After the gene therapy, the children went from being profoundly deaf to having mild to moderate hearing loss

The Guardian - US

Argentinian couple moves to US to allow their toddler to join gene therapy trial

The Lovatos relocated from Guatemala to Ohio for their son, who has the rare genetic disorder Canavan disease

Get all your
news in one place.

100’s of premium titles.
One news app.

Deaf baby can hear after 'mind-blowing' gene therapy treatment

Seven months after her treatment, the baby girl can now respond to her parents' voices without the aid of a cochlear implant.

The Guardian - UK

Great Ormond Street hoping to license gene therapy for ‘bubble baby’ syndrome

Hospital to take unprecedented step after drug firm pulled out despite successful trial of treatment

The Guardian - UK

UK toddler has hearing restored in world first gene therapy trial

Opal Sandy can hear almost perfectly after groundbreaking surgery that took just 16 minutes

Pfizer reports patient death in Duchenne gene therapy study

Pfizer's gene therapy trial for Duchenne muscular dystrophy resulted in a young patient's death from cardiac arrest

Investors Business Daily

Pfizer Wins FDA Approval For $3.5 Million Gene Therapy, Rivaling CSL, Uniqure

The FDA approved Pfizer's hemophilia gene therapy on Friday. But Pfizer stock only inched ahead on the approval early Friday.

3 Standout Penny Stocks to Watch This April

Investing in penny stocks carries substantial risk, but also offers the potential for significant returns. These penny stocks, all with bullish analyst ratings, have considerable upside potential, according to Wall Street.

Gene Therapy Breakthroughs In The 1990S Revolutionized Medical Treatment.

Explore the pivotal era of gene therapy in the 1990s, from groundbreaking advancements to significant challenges, shaping modern regenerative medicine.

People

Joseph Schwartz

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Food and Drug Administration

Micron Technology

Medical Pharmaceuticals

Gilead Sciences Inc

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Macular Degeneration

Places

244,204 stories

102,414 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play